Company / Cost of Revenue
Avalo Therapeutics, Inc. Cost of Revenue History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.3M
FY2023
5-year range
$1.3M / $3.4M
FY2019-FY2023
Trend
-62.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 7 years, ranging from -$566,523 in FY2019 to $3M in FY2022.
Based on SEC 10-K filings.
$1M in FY2023 with a 5-year CAGR of -17.0%.
Improved from $1M to $1M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +62.4%
- 5-Year CAGR
- -17.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -17.0%, indicating a declining trend.
- In FY2023, cost of revenue decreased 62.6% year-over-year.
- Peak cost of revenue was recorded in FY2022.
- Lowest cost of revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.3M | -62.6% |
| FY2022 | $3.4M | +130.3% |
| FY2021 | $1.5M | +397.0% |
| FY2020 | $300.0K | +153.0% |
| FY2019 | -$566.5K | -117.4% |
| FY2018 | $3.3M | +413.0% |
| FY2017 | $635.6K | - |
As of FY2023 · SEC Form 10-K · Last checked Jun 21, 2026